Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: Mechanistic evidence from a tissue culture model

Experimental Biology and Medicine

Volumn 236, Issue 9, 2011, Pages 1036-1050

  Donahue, Renee N ^a   McLaughlin, Patricia J ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cell proliferation; Cyclin dependent inhibitory kinases; Enkephalin; LDN; Low dose naltrexone; OGF; OGFr; Opioid; Opioid antagonist; Opioid growth factor; Opioid growth factor receptor

Indexed keywords

GROWTH FACTOR RECEPTOR; METENKEPHALIN; NALTREXONE; OPIOID GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P21; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CARCINOMA; HUMAN; HUMAN CELL; NECROSIS; OVARY CANCER; PANCREAS CARCINOMA; RECEPTOR BLOCKING; SQUAMOUS CELL CARCINOMA; TISSUE CULTURE;

APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENKEPHALINS; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PROTEIN PRECURSORS; RECEPTORS, OPIOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 80052478909     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.011121     Document Type: Article

References (63)

1. Blumberg H, Dayton HB. Naloxone, naltrexone, and related noroxymorphones. In: Braude MC, Harris LC, May EL, Smith JP, Villarreal JE, eds. Advances in Biochemical Psychopharmacology. 2nd edn. Narcotic Antagonists. New York: Raven Press, 1974:33-43.
2. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG, Limbard LE, eds. The Pharmacological Basis of Therapeutics. 10th edn. New York: McGraw Hill, 2001:569-619
3. Leslie FM. Methods used for the study of opioid receptors. Pharmacol Rev 1987;39:197-249.
4. Sawynok J, Pinsky C, LaBella FS. On the specificity of naloxone as an opiate antagonist. Life Sci 1979;25:1621-32.
5. Gross GJ, Baker JE, Hsu A, Wu HE, Falck JR, Nithipatikom K. Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts. Am J Physiol Heart Circ Physiol 2010;298:H2201-7.
6. Hytrek SD, McLaughlin PJ, Lang CM, Zagon IS. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Letters 1996;101:159-64.
7. Retana-Márquez S, Bonilla-Jaime H, Vázquez-Palacios G, Martínez-García R. Naltrexone effects on male sexual behavior, corticosterone, and testosterone in stressed male rats. Physiol Behav 2009;96:333-42.
8. Sauriyal DS, Jaggi AS, Singh N, Muthuraman A. Investigating the role of endogenous opioids and K(ATP) channels in glycerol-induced acute renal failure. Fundam Clin Pharmacol 2011. [Epub ahead of print]. DOI: 10.1111/j.1472-8206-2011.00936.x
9. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohńs disease. Am J Gastroenterol 2007;102:820-8.
10. Stagg NJ, Mata HP, Ibrahim MM, Henriksen EJ, Porreca F, Vanderah TW, Philip Malan T Jr. Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: role of endogenous opioids. Anesthesiology 2011;114:940-8.
11. Teng L, Zhao J, Wang F, Ma L, Pei G. A GPCR/secretase complex regulates b-and g-secretase specificity for Ab production and contributes to AD pathogenesis. Cell Res 2010;20:138-53.
12. Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE. Opioid receptors and endogenous opioids in diverse human and animal cancers. JNCI 1987;79:1059-65.
13. Zagon IS, McLaughlin PJ. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 1989;480:16-28.
14. Zagon IS, Rahn KA, Turel AP, McLaughlin PJ. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol and Med 2009;234:1383-92.
15. Zagon IS, McLaughlin PJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci 1984;35:409-16.
16. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev 2002;38:351-76.
17. Zagon IS, McLaughlin PJ. Increased brain size and cellular content in infant rats treated with an opiate antagonist. Science 1983;221:1179-80.
18. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science 1983;221:671-3.
19. Zagon IS, McLaughlin PJ. Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res 1987;412:68-72.
20. Zagon IS, McLaughlin PJ. Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acuteopioidantagonist (naltrexone) exposure. MolBrainRes 1995;33:111-20.
21. Zagon IS, Gibo DM, McLaughlin PJ. Ontogeny of zeta (z), the opioid growth factor receptor, in the rat brain. Brain Res 1992;596:149-56.
22. McLaughlin PJ, Zagon IS. Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems. Life Sci 1987;41:1465-72.
23. Zagon IS, McLaughlin PJ. Naloxone prolongs the survival time of mice treated with neuroblastoma. Life Sci 1981;28:1095-102.
24. Zagon IS, McLaughlin PJ. Naloxone modulates body and organ growth of rats: dependency on the duration of opioid receptor blockade and stereospecificity. Pharmacol Biochem Behav 1989;33:325-8.
25. Lahti RA, Collins RJ. Chronic naloxone results in prolonged increases in opiate binding sites in brain. Eur J Pharmacol 1978;51:185-6.
26. Recant L, Voyles NR, Luciano M, Pert CB. Naltrexone reduces weight gain, alters 'b-endorphiń, and reduces insulin output from pancreatic islets of genetically obese mice. Peptides 1980;1:309-13.
27. Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther 1985;232:439-44.
28. Misra AL. Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone. NIDA Res Monogr 1981;28:132-46.
29. Schulz R, Wuster M, Herz A. Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone. Naunyn Schmied Arch Pharmac 1979;306:93-6.
30. Tang AH, Collins RJ. Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat. Eur J Pharmacol 1978;47:473-4.
31. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR. Naltrexone-induced opiate receptor supersensitivity. Brain Res 1982;245:185-92.
32. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 2007;7:5-0.
33. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck. Cancer Res 2007;67:10511-8.
34. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 2009;20:319-27.
35. Donahue RD, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol 2009;296:R1716-25.
36. Bisignani GJ, McLaughlin PJ, Ordille SD, Jarowenko MJ, Zagon IS. Human renal cell proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 1999;162:2186-91.
37. McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 1999;14:991-8.
38. McLaughlin PJ, Zagon IS, Skitzki J. Human neuroblastoma cell growth in tissue culture is regulated by the opioid growth factor. Int J Oncol 1999;14:373-80.
39. McLaughlin PJ, Stack BC, Levin RJ, Fedok F, Zagon IS. Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck. Cancer 2003;97:1701-10.
40. McLaughlin PJ, Zagon IS, Park SS, Conway A, Donahue RN, Goldenberg D. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF)-opioid growth factor receptor (OGFr) axis. BMC Cancer 2009;9:369-0.
41. Zagon IS, Hytrek SD, McLaughlin PJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 1996;271:R511-8.
42. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 1999;14:577-84.
43. Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant on cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol 2009;297:R1154-61.
44. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med 2008;8:968-79.
45. McLaughlin PJ, Verderame MF, Hankins JL, Zagon IS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med 2007;19:421-8.
46. Zagon IS, Verderame MF, Hankins JL, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol 2007;30:775-83.
47. Zagon IS, Verderame MF, McLaughlin PJ. The expression and function of the OGF-OGFr axis-a tonically active negative regulator of growth-in COS cells. Neuropeptides 2003;5:290-7.
48. Zagon IS, McLaughlin PJ. Stereospecific modulation of tumorigenicity by opioid antagonists. Eur J Pharm 1985;113:115-20.
49. Zagon IS, McLaughlin PJ. Endogenous opioid systems regulate growth of neural tumor cells in culture. Brain Res 1989;490:14-25.
50. Fogh J, Trempe G. New human tumor cell lines. In: Fogh J, ed. Human Tumor Cells In Vitro. New York: Plenum Publishing Corp, 1975:115-59.
51. Harker WG, MacKintosh FR, Sikic BI. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res 1983;43:4943-50
52. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 1977;19:128-35.
53. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 1981;41:1751-6.
54. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma. Arch Otolaryngol 1981;107:703-10.
55. Zagon IS, McLaughlin PJ. Production and characterization of polyclonal and monoclonal antibodies to the zeta (z) opioid receptor. Brain Res 1993;630:295-302.
56. Zagon IS, McLaughlin PJ. Opioid antagonist (naltrexone) stimulation of cell proliferation in human and animal neuroblastoma and human fibrosarcoma cells in culture. Neuroscience 1990;37:223-6.
57. Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011;56:2088-97.
58. Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology 2011;216:579-90.
59. Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology 2011;216:173-83.
60. Rahn KA, McLaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis. Brain Res 2011;1381:243-53.
61. Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res 2010;1310:154-61.
62. Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs 2004;15:203-9.
63. Smith JP, Bingaman SI, Mauger DT, Harvey HH, Demers LM, Zagon IS. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials 2010;2010:37-48